SMTI Sanara MedTech Inc.
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial and full-thickness wounds, as well as first and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and it can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties; ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Sanara MedTech (NASDAQ: SMTI)
›
Sanara MedTech (NASDAQ: SMTI) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 108 employees.
The shares were at 32.67 USD on 19 November 2026, up 18.4% over 52 weeks. Its 52-week range is 16.05 USD to 35.52 USD: the price is 8.0% below the high and 103.6% above the low.
Its market capitalisation is 300.00M USD.
Sanara MedTech reports an operating margin of 7.2% and revenue up 8.0% year over year.
Its debt exceeds its cash by 31.90M USD, a debt-to-equity ratio of 8.12. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 3 analysts cover the stock, with an average rating of Hold; their mean price target of 35.00 USD is 7.1% above the current price. The next earnings report is expected on 24 March 2027.